Prostate cancer is currently one of the most common malignancies in older men, and chemotherapy is gaining increasing attention as one of the main treatment modalities with significant clinical benefit for patients, being selectively applied to destructive resistant prostate cancer, hormone-sensitive but with more metastases and hormone-sensitive prostate cancer with multiple high-risk factors, especially with lymph node metastases and Gleason score containing 4 and Prostate cancer with a 5-point component is still controversial and requires multicenter randomized controlled clinical studies with large samples. The common chemotherapeutic agent for prostate cancer is the paclitaxel-like drug docetaxel, and the more common side effects in clinical practice include myelosuppression, nausea, decreased appetite, malaise, and nail deformation and pigmentation. Among them, myelosuppression is mainly manifested as a decrease in neutrophils, which is a common problem in the clinic. Anemia and platelet reduction are relatively rare. During chemotherapy, it is necessary to review the blood routine every week in order to detect myelosuppression in time and carry out graded treatment, which is crucial for patient safety. If the leukocytes are between 2-4×109/L and the neutrophil count is between 1-2×109/L, oral treatment with leukocyte-raising drugs can be administered. Commonly used oral drugs include blood-raising pills, licoquinone, compound saponin tablets, vitamin B4, etc. If the leukocytes are lower than between 2×109/L and the neutrophil count is lower than 1×109/L, treatment with leukocyte-raising injections is required, and currently The whitening injections used by various hospitals and departments may be slightly different, but they all have the same principle, so they can all be used. Other side effects are relatively less symptomatic, and the occurrence of grade 3 or higher is relatively rare, so no special treatment is generally required. The toxicity of docetaxel on liver and kidney function is relatively low, but weekly biochemical tests are still essential in order to monitor liver and kidney function, and patients are encouraged to drink more water during chemotherapy to maintain a daily urine output of more than 1500 ml.